2177-83-5Relevant articles and documents
Magnetic Co3O4/reduced graphene oxide nanocomposite as a superior heterogeneous catalyst for one-pot oxidative esterification of aldehydes to methyl esters
Panwar, Vineeta,Al-Nafiey, Amer,Addad, Ahmed,Sieber, Brigitte,Roussel, Pascal,Boukherroub, Rabah,Jain, Suman L.
, p. 88567 - 88573 (2015/11/09)
A magnetically separable hybrid material consisting of Co3O4 nanoparticles supported on reduced graphene oxide (Co3O4/rGO) was synthesized through a simple co-reduction process of graphene oxide (GO) and cobalt chloride (CoCl2) using sodium borohydride (NaBH4). The Co3O4/rGO heterogeneous catalyst exhibited a high-performance for the oxidative esterification of aldehydes to the corresponding methyl esters using tert-butyl hydroperoxide (TBHP) as an oxidant. Owing to the synergistic effect of rGO support, the hybrid catalyst exhibited superior catalytic activity to the corresponding cobalt oxide catalyst. Importantly, the synthesized hybrid possesses good magnetic properties, which enable facile recovery of the catalyst by using an external magnet.
Highly selective formation of linear esters from terminal and internal alkenes catalysed by palladium complexes of bis-(di-tert-butylphosphinomethyl) benzene
Rodriguez, Cristina Jimenez,Foster, Douglas F.,Eastham, Graham R.,Cole-Hamilton, David J.
, p. 1720 - 1721 (2007/10/03)
The methoxycarbonylation of terminal or internal alkenes catalysed by palladium complexes of bis-(di-tert-butylphosphinomethyl)benzene under mild conditions leads to linear esters in 99% selectivity via a hydride mechanism.
Prostaglandins E and anti-ulcers containing same
-
, (2008/06/13)
The novel 13,14-dihydro-15-keto prostaglandins E of the invention have remarkable preventive effects against ulcers. Further, the novel 13,14-dihydro-15-keto-prostaglandins E of the invention have an advantage that they have none of side effects which prostaglandin E intrinsically has, or can remarakably reduce such effects of the prostaglandin E. Therefore, the novel 13,14-dihydro-15-keto prostaglandins E of the invention are effective for animal and human use for treatment and prevention of ulcers, such as duodenal ulcer and gastric ulcer.